Monitoring Report: Respiratory Viruses – October 2025 Data

Samuel Gratzl*, PhD

Karen G Farrar, PhD*

Duy Do, PhD

Nina Masters, MPH, PhD

Brianna M Goodwin Cartwright, MS

* Denotes co-first author
Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Brianna M Goodwin Cartwright
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: briannac@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through November 02, 2025) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2020 and November 02, 2025. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 830,292 hospitalizations of 758,329 unique patients who tested positive for a respiratory virus between October 01, 2020 and November 02, 2025.

Overall, respiratory virus-associated hospitalizations declined throughout October 2025. By the last week of the month, respiratory virus-associated hospitalizations accounted for 1.3% of all hospitalizations, down from 1.8% at the end of September (-31.8%). COVID-19 hospitalizations declined substantially (−68.2%), while rhinovirus remained the leading cause of virus-associated hospitalizations (0.7%), though it also decreased (−23.7%). Influenza-, HMPV-, parainfluenza- and RSV-associated hospitalizations remained low and relatively stable. Among children aged 0-4 years, respiratory virus-associated hospitalizations were stable over the month at 2.0%. Rhinovirus was the leading cause of virus-associated hospitalizations (1.4%), although RSV-related hospitalizations more than doubled for the second month in a row, now accounting for 0.7% of all hospitalizations in this age group. Test positivity for COVID declined substantially (-56.0%), while test positivity for RSV and influenza rose (+134.6% and +65.2% respectively). Among older adults (65+), respiratory virus-associated hospitalizations declined to 1.2% (-41.5%). COVID-associated hospitalizations declined to 0.4% and test positivity also dropped. Rhinovirus was the leading cause of virus-associated hospitalizations in the older adult age group, now accounting for 0.6% of all

hospitalizations. Test positivity for RSV and influenza increased (+259.0% and 53.7%, respectively).

Discussion: These data highlight overall declines in respiratory virus-associated hospitalizations across age groups during October 2025. In the pediatric population, hospitalization rates remained stable, but RSV-associated hospitalizations increased. Test positivity for RSV and influenza rose in both children and older adults, indicating potential signals of early seasonal circulation. Continued monitoring will be important to track whether these increases translate into increased hospitalization trends as the respiratory virus season progresses, especially among populations at higher risk for severe outcomes.

Trends in surveillance

Overall population

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 29, 2025	1.8%	0.7%	0.1%	0.0%	0.1%	0.0%	0.9%
October 27, 2025	1.3%	0.2%	0.1%	0.0%	0.1%	0.1%	0.7%
Change (percentage)	-31.8%	-68.2%	+116.9%	-30.2%	-15.2%	+281.8%	-23.7%
Difference (percentage points)	-0.6%	-0.5%	+0.1%	-0.0%	-0.0%	+0.1%	-0.2%

Change in positivity rate of weekly respiratory virus tests between September 29, 2025 and October 27, 2025

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 29, 2025	4.1%	6.0%	1.8%	0.6%	3.4%	0.9%	20.7%
October 27, 2025	3.8%	3.0%	3.3%	0.5%	4.0%	2.4%	19.3%
Change (percentage)	-7.4%	-51.1%	+85.3%	-24.1%	+17.4%	+165.9%	-6.9%
Difference (percentage points)	-0.3%	-3.1%	+1.5%	-0.1%	+0.6%	+1.5%	-1.4%

In the last week of October 2025, respiratory virus-associated hospitalizations accounted for 1.3% of all hospitalizations, a decrease from 1.8% at the beginning of the month (-31.8%). COVID-associated hospitalizations decreased substantially, from 0.7% to 0.2% of all hospitalizations (-68.2%), and rhinovirus-associated hospitalizations decreased slightly to 0.7% of all hospitalizations. Influenza-, HMPV-, parainfluenza-, and RSV-associated hospitalizations all remained low and stable across the month.

RSV and influenza test positivity increased notably (+165.9% and +85.3%, respectively), while COVID test positivity fell sharply (–51.1%). Parainfluenza test positivity increased slightly (+17.4%), HMPV remained steady and low, and rhinovirus continued to show the highest positivity levels (19.3%). These data suggest that respiratory virus–associated hospitalizations remained low overall; at the end of October rhinovirus accounted for the largest proportion of virus-associated hospitalizations and had the highest rate of test positivity. At the same time, increases in RSV and influenza test positivity were observed in the overall population, potentially reflecting early signs of seasonal circulation.

Infants and children (age 0-4)

Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five

Change in rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions between September 29, 2025 and October 27, 2025 for infants and children under five

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 29, 2025	1.8%	0.2%	0.0%	0.0%	0.1%	0.3%	1.4%
October 27, 2025	2.0%	0.1%	0.2%	n/a	0.2%	0.7%	1.2%
Change (percentage)	+10.0%	-69.2%	+823.2%		+25.4%	+135.3%	-12.9%
Difference (percentage points)	+0.2%	-0.1%	+0.1%		+0.0%	+0.4%	-0.2%

Weekly test positivity rate since October 2020 for infants and children under five

Change in weekly test positivity rate between September 29, 2025 and October 27, 2025 for infants and children under five

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 29, 2025	7.1%	4.3%	1.9%	1.7%	10.2%	3.7%	50.5%
October 27, 2025	7.7%	1.9%	3.2%	0.7%	12.2%	8.7%	46.3%
Change (percentage)	+8.9%	-56.0%	+65.2%	-55.8%	+20.4%	+134.6%	-8.3%
Difference (percentage points)	+0.6%	-2.4%	+1.3%	-0.9%	+2.1%	+5.0%	-4.2%

In the population aged 0–4 years, respiratory virus–associated hospitalizations remained relatively stable throughout October 2025 and are now at a rate of 2.0% of all hospitalizations in this age group. For the second month in a row, the rate of RSV-associated hospitalizations more than doubled; however the overall rate continues to

represent a small proportion of all hospitalizations within this age group (0.7%). COVID-, influenza-, HMPV-, parainfluenza-, and rhinovirus-associated hospitalizations remained relatively stable and low across the month.

In this pediatric population, RSV test positivity more than doubled (+134.6%), and influenza test positivity increased moderately (+65.2%). COVID and HMPV test positivity declined (−56.0% and −55.8%, respectively), while parainfluenza rose slightly (+20.4%). Rhinovirus remained the virus with the highest test positivity rate (46.3%) despite a slight decrease (−8.3%). These data suggest that respiratory virus–associated hospitalizations are at moderate levels among young children, with rhinovirus accounting for the largest proportion in both hospitalizations and test positivity, and the rate of RSV- and influenza-associated hospitalizations more than doubled, suggesting rising circulation among young children.

Older adults (age 65 and over)

Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older

Change in rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions between September 29, 2025 and October 27, 2025 for adults 65 years or older

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 29, 2025	2.1%	1.1%	0.1%	0.0%	0.1%	0.0%	0.8%
October 27, 2025	1.2%	0.4%	0.1%	0.0%	0.1%	0.1%	0.6%
Change (percentage)	-41.5%	-67.5%	+63.6%	+11.1%	-32.7%	+631.9%	-28.7%
Difference (percentage points)	-0.9%	-0.8%	+0.1%	+0.0%	-0.0%	+0.1%	-0.2%

Weekly test positivity rate since October 2020
for adults 65 years or older

Change in weekly test positivity rate between September 29, 2025 and October 27, 2025
for adults 65 years or older

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 29, 2025	3.4%	7.6%	1.0%	0.4%	1.2%	0.2%	9.1%
October 27, 2025	2.2%	3.3%	1.5%	0.3%	1.1%	0.7%	8.1%
Change (percentage)	-34.2%	-56.2%	+53.7%	-14.2%	-13.7%	+259.0%	-11.2%
Difference (percentage points)	-1.2%	-4.3%	+0.5%	-0.1%	-0.2%	+0.5%	-1.0%

Among adults aged 65 years and older, respiratory virus–associated hospitalizations accounted for 1.2% of all hospitalizations in the last week of October 2025, a decrease from 2.1% at the beginning of the month (-41.5%). Rhinovirus-associated hospitalizations were stable and accounted for 0.6% of all hospitalizations in this age group, while COVID-associated hospitalizations represented 0.4% and declined steadily across the month. RSV-, HMPV-, influenza-, and parainfluenza-associated hospitalizations remained low and stable throughout the month.

COVID test positivity declined substantially (−56.2%), while RSV and influenza test positivity increased (+259.0% and +53.7%, respectively). HMPV and parainfluenza remained relatively stable across the month, and rhinovirus continued to have the highest positivity rate (8.1%) with a slight decline (−11.2%). These data indicate that respiratory virus–associated hospitalizations remained low among older adults, with RSV and influenza showing early signs of increased positivity across the month.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults

(Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2020 and November 02, 2025 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record

(EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on November 10, 2025 and included de-identified patient care data primarily located across ten states: California, Florida, Texas, Virginia, Illinois, Washington, Ohio, Michigan, Arizona, and Wisconsin.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 830,292 hospitalizations of 758,329 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	182,604 (100.00%)	193,521 (100.00%)	133,029 (100.00%)	131,149 (100.00%)	113,809 (100.00%)	4,217 (100.00%)	758,329 (100.00%)
Age Group							
< 6 months	1,062 (0.58%)	2,240 (1.16%)	2,981 (2.24%)	2,458 (1.87%)	2,198 (1.93%)	116 (2.75%)	11,055 (1.46%)
6 - <12 months	436 (0.24%)	1,017 (0.53%)	1,459 (1.10%)	1,331 (1.01%)	1,330 (1.17%)	53 (1.26%)	5,626 (0.74%)
1 - <2 years	738 (0.40%)	1,422 (0.73%)	1,996 (1.50%)	1,746 (1.33%)	1,967 (1.73%)	110 (2.61%)	7,979 (1.05%)
2 - 4 years	726 (0.40%)	1,962 (1.01%)	2,790 (2.10%)	2,147 (1.64%)	2,396 (2.11%)	139 (3.30%)	10,160 (1.34%)
5 - 17 years	1,519 (0.83%)	2,668 (1.38%)	3,027 (2.28%)	2,937 (2.24%)	3,206 (2.82%)	206 (4.88%)	13,563 (1.79%)
18 - 49 years	41,993 (23.00%)	41,089 (21.23%)	18,840 (14.16%)	18,366 (14.00%)	16,803 (14.76%)	690 (16.36%)	137,781 (18.17%)
50 - 64 years	47,317 (25.91%)	41,189 (21.28%)	22,133 (16.64%)	21,984 (16.76%)	19,763 (17.37%)	727 (17.24%)	153,113 (20.19%)
65 - 74 years	38,225 (20.93%)	39,893 (20.61%)	26,961 (20.27%)	27,264 (20.79%)	23,381 (20.54%)	802 (19.02%)	156,526 (20.64%)
75 - 84 years	32,279 (17.68%)	38,006 (19.64%)	31,015 (23.31%)	31,603 (24.10%)	26,121 (22.95%)	860 (20.39%)	159,884 (21.08%)
85+ years	18,309 (10.03%)	24,035 (12.42%)	21,827 (16.41%)	21,313 (16.25%)	16,644 (14.62%)	514 (12.19%)	102,642 (13.54%)
Sex							
Female	89,675 (49.11%)	99,755 (51.55%)	70,001 (52.62%)	69,025 (52.63%)	60,431 (53.10%)	2,160 (51.22%)	391,047 (51.57%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Male	92,333 (50.56%)	93,115 (48.12%)	62,519 (47.00%)	61,679 (47.03%)	53,027 (46.59%)	2,011 (47.69%)	364,684 (48.09%)
Other	3 (0.00%)	1 (0.00%)	4 (0.00%)	1 (0.00%)	1 (0.00%)	0	10 (0.00%)
Unknown	593 (0.32%)	650 (0.34%)	505 (0.38%)	444 (0.34%)	350 (0.31%)	46 (1.09%)	2,588 (0.34%)
Race							
White	119,641 (65.52%)	133,272 (68.87%)	91,431 (68.73%)	87,531 (66.74%)	76,299 (67.04%)	2,684 (63.65%)	510,858 (67.37%)
Black or African American	27,475 (15.05%)	27,023 (13.96%)	17,617 (13.24%)	18,800 (14.33%)	16,213 (14.25%)	685 (16.24%)	107,813 (14.22%)
Asian	3,448 (1.89%)	3,513 (1.82%)	3,013 (2.26%)	3,048 (2.32%)	2,788 (2.45%)	102 (2.42%)	15,912 (2.10%)
Native Hawaiian or Other Pacific Islander	959 (0.53%)	991 (0.51%)	732 (0.55%)	749 (0.57%)	707 (0.62%)	30 (0.71%)	4,168 (0.55%)
American Indian or Alaska Native	1,082 (0.59%)	1,203 (0.62%)	844 (0.63%)	741 (0.57%)	667 (0.59%)	29 (0.69%)	4,566 (0.60%)
Other Race	9,689 (5.31%)	7,737 (4.00%)	6,023 (4.53%)	6,699 (5.11%)	7,074 (6.22%)	310 (7.35%)	37,532 (4.95%)
Unknown	20,310 (11.12%)	19,782 (10.22%)	13,369 (10.05%)	13,581 (10.36%)	10,061 (8.84%)	377 (8.94%)	77,480 (10.22%)
Ethnicity							
Hispanic or Latino	21,529 (11.79%)	16,802 (8.68%)	12,483 (9.38%)	13,746 (10.48%)	14,140 (12.42%)	616 (14.61%)	79,316 (10.46%)
Not Hispanic or Latino	141,050 (77.24%)	158,417 (81.86%)	108,774 (81.77%)	106,268 (81.03%)	92,152 (80.97%)	3,384 (80.25%)	610,045 (80.45%)
Unknown	20,025 (10.97%)	18,302 (9.46%)	11,772 (8.85%)	11,135 (8.49%)	7,517 (6.60%)	217 (5.15%)	68,968 (9.09%)
Virus							
COVID	171,080 (93.69%)	168,833 (87.24%)	78,318 (58.87%)	68,002 (51.85%)	31,423 (27.61%)	1,318 (31.25%)	518,974 (68.44%)
HMPV	86 (0.05%)	2,659 (1.37%)	4,640 (3.49%)	3,916 (2.99%)	5,072 (4.46%)	61 (1.45%)	16,434 (2.17%)
RSV	1,866 (1.02%)	4,437 (2.29%)	8,366 (6.29%)	10,402 (7.93%)	11,009 (9.67%)	191 (4.53%)	36,271 (4.78%)
influenza	2,465 (1.35%)	7,007 (3.62%)	23,177 (17.42%)	28,576 (21.79%)	40,600 (35.67%)	238 (5.64%)	102,063 (13.46%)
parainfluenza	1,318 (0.72%)	2,214 (1.14%)	4,279 (3.22%)	4,468 (3.41%)	5,049 (4.44%)	261 (6.19%)	17,589 (2.32%)
rhinovirus	5,789 (3.17%)	8,371 (4.33%)	14,249 (10.71%)	15,785 (12.04%)	20,656 (18.15%)	2,148 (50.94%)	66,998 (8.83%)
Comorbidity							
Asthma	15,923 (8.72%)	19,697 (10.18%)	16,714 (12.56%)	17,735 (13.52%)	17,427 (15.31%)	654 (15.51%)	88,150 (11.62%)
Chronic Lung Disease	11,634 (6.37%)	13,490 (6.97%)	10,802 (8.12%)	11,031 (8.41%)	11,088 (9.74%)	412 (9.77%)	58,457 (7.71%)
Chronic Obstructive Pulmonary Disease	21,621 (11.84%)	30,528 (15.78%)	25,729 (19.34%)	26,693 (20.35%)	24,189 (21.25%)	834 (19.78%)	129,594 (17.09%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020

Test positivity rate over time

We included 66,344,749 lab results with known results of which 6,049,234 were positive. The test positivity rate is shown in Figure 3.

Figure 3: Weekly test positivity rate since October 2020

COVID-19

Our COVID study population consists of 538,269 hospitalizations of 518,974 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	171,080 (100.00%)	168,833 (100.00%)	78,318 (100.00%)	68,002 (100.00%)	31,423 (100.00%)	1,318 (100.00%)	518,974 (100.00%)
Age Group							
< 6 months	272 (0.16%)	699 (0.41%)	365 (0.47%)	337 (0.50%)	210 (0.67%)	10 (0.76%)	1,893 (0.36%)
6 - <12 months	43 (0.03%)	227 (0.13%)	161 (0.21%)	169 (0.25%)	108 (0.34%)	3 (0.23%)	711 (0.14%)
1 - <2 years	72 (0.04%)	200 (0.12%)	117 (0.15%)	173 (0.25%)	122 (0.39%)	7 (0.53%)	691 (0.13%)
2 - 4 years	112 (0.07%)	296 (0.18%)	112 (0.14%)	114 (0.17%)	78 (0.25%)	1 (0.08%)	713 (0.14%)
5 - 17 years	924 (0.54%)	1,319 (0.78%)	440 (0.56%)	330 (0.49%)	167 (0.53%)	8 (0.61%)	3,188 (0.61%)
18 - 49 years	39,896 (23.32%)	37,203 (22.04%)	10,167 (12.98%)	7,554 (11.11%)	3,630 (11.55%)	161 (12.22%)	98,611 (19.00%)
50 - 64 years	45,179 (26.41%)	37,095 (21.97%)	12,235 (15.62%)	10,042 (14.77%)	4,376 (13.93%)	186 (14.11%)	109,113 (21.02%)
65 - 74 years	36,422 (21.29%)	35,840 (21.23%)	16,890 (21.57%)	14,934 (21.96%)	6,667 (21.22%)	302 (22.91%)	111,055 (21.40%)
75 - 84 years	30,783 (17.99%)	34,353 (20.35%)	21,729 (27.74%)	20,016 (29.43%)	9,460 (30.11%)	372 (28.22%)	116,713 (22.49%)
85+ years	17,377 (10.16%)	21,601 (12.79%)	16,102 (20.56%)	14,333 (21.08%)	6,605 (21.02%)	268 (20.33%)	76,286 (14.70%)
Sex							
Female	83,702 (48.93%)	86,661 (51.33%)	40,550 (51.78%)	34,697 (51.02%)	16,198 (51.55%)	661 (50.15%)	262,469 (50.57%)
Male	86,822 (50.75%)	81,600 (48.33%)	37,452 (47.82%)	33,027 (48.57%)	15,073 (47.97%)	634 (48.10%)	254,608 (49.06%)
Other	3 (0.00%)	1 (0.00%)	2 (0.00%)	1 (0.00%)	0	0	7 (0.00%)
Unknown	553 (0.32%)	571 (0.34%)	314 (0.40%)	277 (0.41%)	152 (0.48%)	23 (1.75%)	1,890 (0.36%)
Race							
White	112,495 (65.76%)	116,764 (69.16%)	56,081 (71.61%)	47,916 (70.46%)	22,261 (70.84%)	898 (68.13%)	356,415 (68.68%)
Black or African American	25,504 (14.91%)	23,561 (13.96%)	9,244 (11.80%)	8,234 (12.11%)	3,959 (12.60%)	164 (12.44%)	70,666 (13.62%)
Asian	3,241 (1.89%)	2,962 (1.75%)	1,685 (2.15%)	1,681 (2.47%)	764 (2.43%)	44 (3.34%)	10,377 (2.00%)
Native Hawaiian or Other Pacific Islander	867 (0.51%)	748 (0.44%)	302 (0.39%)	292 (0.43%)	141 (0.45%)	6 (0.46%)	2,356 (0.45%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
American Indian or Alaska Native	992 (0.58%)	979 (0.58%)	404 (0.52%)	363 (0.53%)	169 (0.54%)	8 (0.61%)	2,915 (0.56%)
Other Race	9,030 (5.28%)	6,424 (3.80%)	2,735 (3.49%)	2,677 (3.94%)	1,274 (4.05%)	68 (5.16%)	22,208 (4.28%)
Unknown	18,951 (11.08%)	17,395 (10.30%)	7,867 (10.04%)	6,839 (10.06%)	2,855 (9.09%)	130 (9.86%)	54,037 (10.41%)
Ethnicity							
Hispanic or Latino	20,327 (11.88%)	13,802 (8.17%)	5,583 (7.13%)	5,487 (8.07%)	2,711 (8.63%)	128 (9.71%)	48,038 (9.26%)
Not Hispanic or Latino	132,031 (77.18%)	138,937 (82.29%)	65,733 (83.93%)	56,685 (83.36%)	26,518 (84.39%)	1,110 (84.22%)	421,014 (81.12%)
Unknown	18,722 (10.94%)	16,094 (9.53%)	7,002 (8.94%)	5,830 (8.57%)	2,194 (6.98%)	80 (6.07%)	49,922 (9.62%)
Comorbidity							
Asthma	14,090 (8.24%)	15,857 (9.39%)	8,105 (10.35%)	7,707 (11.33%)	3,868 (12.31%)	157 (11.91%)	49,784 (9.59%)
Chronic Lung Disease	10,606 (6.20%)	11,274 (6.68%)	6,060 (7.74%)	5,597 (8.23%)	2,847 (9.06%)	140 (10.62%)	36,524 (7.04%)
Chronic Obstructive Pulmonary Disease	19,393 (11.34%)	25,706 (15.23%)	14,745 (18.83%)	13,886 (20.42%)	6,637 (21.12%)	276 (20.94%)	80,643 (15.54%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends.

Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2020

Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 33,816,630 COVID lab results with known results of which 3,657,148 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends.

Figure 6: Weekly COVID test positivity rate since October 2020

Figure 7: Weekly COVID test positivity rate by season

Influenza

Our influenza study population consists of 119,853 hospitalizations of 102,063 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	2,465 (100.00%)	7,007 (100.00%)	23,177 (100.00%)	28,576 (100.00%)	40,600 (100.00%)	238 (100.00%)	102,063 (100.00%)
Age Group							
< 6 months	9 (0.37%)	29 (0.41%)	93 (0.40%)	103 (0.36%)	109 (0.27%)	2 (0.84%)	345 (0.34%)
6 - <12 months	9 (0.37%)	23 (0.33%)	87 (0.38%)	61 (0.21%)	90 (0.22%)	2 (0.84%)	272 (0.27%)
1 - <2 years	10 (0.41%)	32 (0.46%)	126 (0.54%)	102 (0.36%)	144 (0.35%)	2 (0.84%)	416 (0.41%)
2 - 4 years	21 (0.85%)	85 (1.21%)	285 (1.23%)	247 (0.86%)	249 (0.61%)	2 (0.84%)	889 (0.87%)
5 - 17 years	24 (0.97%)	164 (2.34%)	653 (2.82%)	695 (2.43%)	810 (2.00%)	18 (7.56%)	2,364 (2.32%)
18 - 49 years	351 (14.24%)	1,461 (20.85%)	4,456 (19.23%)	5,859 (20.50%)	6,766 (16.67%)	32 (13.45%)	18,925 (18.54%)
50 - 64 years	568 (23.04%)	1,330 (18.98%)	5,018 (21.65%)	6,373 (22.30%)	8,516 (20.98%)	41 (17.23%)	21,846 (21.40%)
65 - 74 years	560 (22.72%)	1,419 (20.25%)	5,036 (21.73%)	6,322 (22.12%)	9,346 (23.02%)	56 (23.53%)	22,739 (22.28%)
75 - 84 years	530 (21.50%)	1,415 (20.19%)	4,651 (20.07%)	5,679 (19.87%)	9,228 (22.73%)	60 (25.21%)	21,563 (21.13%)
85+ years	383 (15.54%)	1,049 (14.97%)	2,772 (11.96%)	3,135 (10.97%)	5,342 (13.16%)	23 (9.66%)	12,704 (12.45%)
Sex							
Female	1,211 (49.13%)	3,893 (55.56%)	12,788 (55.18%)	15,861 (55.50%)	22,207 (54.70%)	119 (50.00%)	56,079 (54.95%)
Male	1,231 (49.94%)	3,073 (43.86%)	10,281 (44.36%)	12,623 (44.17%)	18,303 (45.08%)	118 (49.58%)	45,629 (44.71%)
Other	0	0	2 (0.01%)	0	0	0	2 (0.00%)
Unknown	23 (0.93%)	41 (0.59%)	106 (0.46%)	92 (0.32%)	90 (0.22%)	1 (0.42%)	353 (0.35%)
Race							
White	1,263 (51.24%)	4,461 (63.66%)	14,419 (62.21%)	17,198 (60.18%)	27,069 (66.67%)	138 (57.98%)	64,548 (63.24%)
Black or African American	513 (20.81%)	1,104 (15.76%)	4,194 (18.10%)	5,819 (20.36%)	6,098 (15.02%)	34 (14.29%)	17,762 (17.40%)
Asian	25 (1.01%)	121 (1.73%)	442 (1.91%)	567 (1.98%)	1,025 (2.52%)	14 (5.88%)	2,194 (2.15%)
Native Hawaiian or Other Pacific Islander	7 (0.28%)	59 (0.84%)	148 (0.64%)	192 (0.67%)	215 (0.53%)	2 (0.84%)	623 (0.61%)
American Indian or Alaska Native	18 (0.73%)	57 (0.81%)	174 (0.75%)	160 (0.56%)	252 (0.62%)	1 (0.42%)	662 (0.65%)
Other Race	76 (3.08%)	267 (3.81%)	1,126 (4.86%)	1,483 (5.19%)	2,532 (6.24%)	24 (10.08%)	5,508 (5.40%)
Unknown	563 (22.84%)	938 (13.39%)	2,674 (11.54%)	3,157 (11.05%)	3,409 (8.40%)	25 (10.50%)	10,766 (10.55%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Ethnicity							
Hispanic or Latino	71 (2.88%)	599 (8.55%)	2,173 (9.38%)	2,884 (10.09%)	4,826 (11.89%)	44 (18.49%)	10,597 (10.38%)
Not Hispanic or Latino	1,824 (74.00%)	5,529 (78.91%)	18,537 (79.98%)	22,933 (80.25%)	33,125 (81.59%)	184 (77.31%)	82,132 (80.47%)
Unknown	570 (23.12%)	879 (12.54%)	2,467 (10.64%)	2,759 (9.65%)	2,649 (6.52%)	10 (4.20%)	9,334 (9.15%)
Comorbidity							
Asthma	233 (9.45%)	1,009 (14.40%)	3,481 (15.02%)	4,185 (14.65%)	6,245 (15.38%)	35 (14.71%)	15,188 (14.88%)
Chronic Lung Disease	110 (4.46%)	581 (8.29%)	1,955 (8.44%)	2,383 (8.34%)	4,001 (9.85%)	28 (11.76%)	9,058 (8.87%)
Chronic Obstructive Pulmonary Disease	430 (17.44%)	1,523 (21.74%)	4,984 (21.50%)	5,955 (20.84%)	9,016 (22.21%)	31 (13.03%)	21,939 (21.50%)

Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends.

Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 18,392,693 influenza lab results with known results of which 1,598,779 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Weekly influenza test positivity rate since October 2020

Figure 11: Weekly influenza test positivity rate by season

Human metapneumovirus (HMPV)

Our HMPV study population consists of 19,744 hospitalizations of 16,434 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	86 (100.00%)	2,659 (100.00%)	4,640 (100.00%)	3,916 (100.00%)	5,072 (100.00%)	61 (100.00%)	16,434 (100.00%)
Age Group							
< 6 months	1 (1.16%)	55 (2.07%)	156 (3.36%)	82 (2.09%)	99 (1.95%)	1 (1.64%)	394 (2.40%)
6 - <12 months	2 (2.33%)	85 (3.20%)	137 (2.95%)	101 (2.58%)	112 (2.21%)	1 (1.64%)	438 (2.67%)
1 - <2 years	8 (9.30%)	141 (5.30%)	181 (3.90%)	102 (2.60%)	133 (2.62%)	2 (3.28%)	567 (3.45%)
2 - 4 years	11 (12.79%)	212 (7.97%)	312 (6.72%)	165 (4.21%)	167 (3.29%)	3 (4.92%)	870 (5.29%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
5 - 17 years	2 (2.33%)	109 (4.10%)	175 (3.77%)	120 (3.06%)	134 (2.64%)	2 (3.28%)	542 (3.30%)
18 - 49 years	13 (15.12%)	338 (12.71%)	505 (10.88%)	480 (12.26%)	628 (12.38%)	7 (11.48%)	1,971 (11.99%)
50 - 64 years	20 (23.26%)	507 (19.07%)	801 (17.26%)	728 (18.59%)	866 (17.07%)	15 (24.59%)	2,937 (17.87%)
65 - 74 years	7 (8.14%)	482 (18.13%)	876 (18.88%)	762 (19.46%)	1,024 (20.19%)	17 (27.87%)	3,168 (19.28%)
75 - 84 years	14 (16.28%)	461 (17.34%)	906 (19.53%)	857 (21.88%)	1,150 (22.67%)	8 (13.11%)	3,396 (20.66%)
85+ years	8 (9.30%)	269 (10.12%)	591 (12.74%)	519 (13.25%)	759 (14.96%)	5 (8.20%)	2,151 (13.09%)
Sex							
Female	41 (47.67%)	1,526 (57.39%)	2,719 (58.60%)	2,385 (60.90%)	2,947 (58.10%)	32 (52.46%)	9,650 (58.72%)
Male	44 (51.16%)	1,126 (42.35%)	1,911 (41.19%)	1,520 (38.82%)	2,115 (41.70%)	28 (45.90%)	6,744 (41.04%)
Unknown	1 (1.16%)	7 (0.26%)	10 (0.22%)	11 (0.28%)	10 (0.20%)	1 (1.64%)	40 (0.24%)
Race							
White	57 (66.28%)	1,935 (72.77%)	3,307 (71.27%)	2,618 (66.85%)	3,473 (68.47%)	40 (65.57%)	11,430 (69.55%)
Black or African American	7 (8.14%)	308 (11.58%)	473 (10.19%)	463 (11.82%)	632 (12.46%)	11 (18.03%)	1,894 (11.52%)
Asian	0	53 (1.99%)	127 (2.74%)	91 (2.32%)	138 (2.72%)	1 (1.64%)	410 (2.49%)
Native Hawaiian or Other Pacific Islander	0	18 (0.68%)	16 (0.34%)	16 (0.41%)	20 (0.39%)	1 (1.64%)	71 (0.43%)
American Indian or Alaska Native	0	19 (0.71%)	36 (0.78%)	24 (0.61%)	23 (0.45%)	0	102 (0.62%)
Other Race	10 (11.63%)	139 (5.23%)	315 (6.79%)	310 (7.92%)	346 (6.82%)	5 (8.20%)	1,125 (6.85%)
Unknown	12 (13.95%)	187 (7.03%)	366 (7.89%)	394 (10.06%)	440 (8.68%)	3 (4.92%)	1,402 (8.53%)
Ethnicity							
Hispanic or Latino	22 (25.58%)	325 (12.22%)	654 (14.09%)	627 (16.01%)	740 (14.59%)	12 (19.67%)	2,380 (14.48%)
Not Hispanic or Latino	55 (63.95%)	2,146 (80.71%)	3,697 (79.68%)	3,001 (76.63%)	4,013 (79.12%)	47 (77.05%)	12,959 (78.85%)
Unknown	9 (10.47%)	188 (7.07%)	289 (6.23%)	288 (7.35%)	319 (6.29%)	2 (3.28%)	1,095 (6.66%)
Comorbidity							
Asthma	11 (12.79%)	395 (14.86%)	746 (16.08%)	669 (17.08%)	852 (16.80%)	9 (14.75%)	2,682 (16.32%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Chronic Lung Disease	10 (11.63%)	292 (10.98%)	464 (10.00%)	377 (9.63%)	563 (11.10%)	8 (13.11%)	1,714 (10.43%)
Chronic Obstructive Pulmonary Disease	18 (20.93%)	544 (20.46%)	957 (20.62%)	790 (20.17%)	1,103 (21.75%)	9 (14.75%)	3,421 (20.82%)

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends.

Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2020

Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 2,145,408 HMPV lab results with known results of which 51,957 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends.

Figure 14: Weekly HMPV test positivity rate since October 2020

Figure 15: Weekly HMPV test positivity rate by season

Parainfluenza virus

Our parainfluenza study population consists of 21,875 hospitalizations of 17,589 unique patients (Table 5).

Table 5: Parainfluenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	1,318 (100.00%)	2,214 (100.00%)	4,279 (100.00%)	4,468 (100.00%)	5,049 (100.00%)	261 (100.00%)	17,589 (100.00%)
Age Group							
< 6 months	59 (4.48%)	89 (4.02%)	194 (4.53%)	137 (3.07%)	137 (2.71%)	9 (3.45%)	625 (3.55%)
6 - <12 months	45 (3.41%)	68 (3.07%)	118 (2.76%)	95 (2.13%)	85 (1.68%)	8 (3.07%)	419 (2.38%)
1 - <2 years	76 (5.77%)	87 (3.93%)	180 (4.21%)	138 (3.09%)	142 (2.81%)	13 (4.98%)	636 (3.62%)
2 - 4 years	73 (5.54%)	122 (5.51%)	210 (4.91%)	154 (3.45%)	147 (2.91%)	16 (6.13%)	722 (4.10%)
5 - 17 years	61 (4.63%)	101 (4.56%)	180 (4.21%)	120 (2.69%)	154 (3.05%)	21 (8.05%)	637 (3.62%)
18 - 49 years	203 (15.40%)	297 (13.41%)	527 (12.32%)	546 (12.22%)	631 (12.50%)	34 (13.03%)	2,238 (12.72%)
50 - 64 years	282 (21.40%)	461 (20.82%)	799 (18.67%)	816 (18.26%)	893 (17.69%)	46 (17.62%)	3,297 (18.74%)
65 - 74 years	224 (17.00%)	428 (19.33%)	790 (18.46%)	956 (21.40%)	1,058 (20.95%)	47 (18.01%)	3,503 (19.92%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
75 - 84 years	196 (14.87%)	327 (14.77%)	772 (18.04%)	956 (21.40%)	1,100 (21.79%)	39 (14.94%)	3,390 (19.27%)
85+ years	99 (7.51%)	234 (10.57%)	509 (11.90%)	550 (12.31%)	702 (13.90%)	28 (10.73%)	2,122 (12.06%)
Sex							
Female	710 (53.87%)	1,251 (56.50%)	2,315 (54.10%)	2,440 (54.61%)	2,776 (54.98%)	125 (47.89%)	9,617 (54.68%)
Male	605 (45.90%)	961 (43.41%)	1,948 (45.52%)	2,020 (45.21%)	2,265 (44.86%)	134 (51.34%)	7,933 (45.10%)
Unknown	3 (0.23%)	2 (0.09%)	16 (0.37%)	8 (0.18%)	8 (0.16%)	2 (0.77%)	39 (0.22%)
Race							
White	901 (68.36%)	1,568 (70.82%)	2,936 (68.61%)	2,934 (65.67%)	3,412 (67.58%)	177 (67.82%)	11,928 (67.82%)
Black or African American	178 (13.51%)	264 (11.92%)	517 (12.08%)	549 (12.29%)	633 (12.54%)	34 (13.03%)	2,175 (12.37%)
Asian	17 (1.29%)	49 (2.21%)	108 (2.52%)	109 (2.44%)	126 (2.50%)	3 (1.15%)	412 (2.34%)
Native Hawaiian or Other Pacific Islander	6 (0.46%)	9 (0.41%)	22 (0.51%)	37 (0.83%)	20 (0.40%)	2 (0.77%)	96 (0.55%)
American Indian or Alaska Native	15 (1.14%)	20 (0.90%)	38 (0.89%)	32 (0.72%)	30 (0.59%)	3 (1.15%)	138 (0.78%)
Other Race	80 (6.07%)	109 (4.92%)	306 (7.15%)	310 (6.94%)	367 (7.27%)	22 (8.43%)	1,194 (6.79%)
Unknown	121 (9.18%)	195 (8.81%)	352 (8.23%)	497 (11.12%)	461 (9.13%)	20 (7.66%)	1,646 (9.36%)
Ethnicity							
Hispanic or Latino	140 (10.62%)	257 (11.61%)	578 (13.51%)	660 (14.77%)	687 (13.61%)	34 (13.03%)	2,356 (13.39%)
Not Hispanic or Latino	1,071 (81.26%)	1,781 (80.44%)	3,361 (78.55%)	3,461 (77.46%)	4,054 (80.29%)	210 (80.46%)	13,938 (79.24%)
Unknown	107 (8.12%)	176 (7.95%)	340 (7.95%)	347 (7.77%)	308 (6.10%)	17 (6.51%)	1,295 (7.36%)
Comorbidity							
Asthma	224 (17.00%)	393 (17.75%)	691 (16.15%)	733 (16.41%)	846 (16.76%)	31 (11.88%)	2,918 (16.59%)
Chronic Lung Disease	144 (10.93%)	275 (12.42%)	468 (10.94%)	487 (10.90%)	588 (11.65%)	24 (9.20%)	1,986 (11.29%)
Chronic Obstructive Pulmonary Disease	322 (24.43%)	549 (24.80%)	1,013 (23.67%)	1,143 (25.58%)	1,237 (24.50%)	43 (16.48%)	4,307 (24.49%)

Hospitalization rate over time

The rate of parainfluenza-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends.

Figure 16: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 17: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 2,224,387 parainfluenza lab results with known results of which 79,879 were positive. The parainfluenza test positivity rate is shown in Figure 18. Figure 19 shows yearly trends.

Figure 18: Weekly parainfluenza test positivity rate since October 2020

Figure 19: Weekly parainfluenza test positivity rate by season

Respiratory syncytial virus (RSV)

Our RSV study population consists of 47,000 hospitalizations of 36,271 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	1,866 (100.00%)	4,437 (100.00%)	8,366 (100.00%)	10,402 (100.00%)	11,009 (100.00%)	191 (100.00%)	36,271 (100.00%)
Age Group							
< 6 months	419 (22.45%)	769 (17.33%)	1,385 (16.56%)	1,052 (10.11%)	823 (7.48%)	30 (15.71%)	4,478 (12.35%)
6 - <12 months	146 (7.82%)	321 (7.23%)	545 (6.51%)	494 (4.75%)	491 (4.46%)	11 (5.76%)	2,008 (5.54%)
1 - <2 years	181 (9.70%)	361 (8.14%)	639 (7.64%)	533 (5.12%)	584 (5.30%)	25 (13.09%)	2,323 (6.40%)
2 - 4 years	134 (7.18%)	372 (8.38%)	734 (8.77%)	461 (4.43%)	614 (5.58%)	13 (6.81%)	2,328 (6.42%)
5 - 17 years	38 (2.04%)	112 (2.52%)	254 (3.04%)	223 (2.14%)	253 (2.30%)	6 (3.14%)	886 (2.44%)
18 - 49 years	189 (10.13%)	398 (8.97%)	702 (8.39%)	933 (8.97%)	1,123 (10.20%)	29 (15.18%)	3,374 (9.30%)
50 - 64 years	249 (13.34%)	551 (12.42%)	981 (11.73%)	1,522 (14.63%)	1,646 (14.95%)	17 (8.90%)	4,966 (13.69%)
65 - 74 years	233 (12.49%)	569 (12.82%)	1,132 (13.53%)	1,780 (17.11%)	1,881 (17.09%)	22 (11.52%)	5,617 (15.49%)
75 - 84 years	173 (9.27%)	605 (13.64%)	1,178 (14.08%)	1,971 (18.95%)	2,141 (19.45%)	20 (10.47%)	6,088 (16.78%)
85+ years	104 (5.57%)	379 (8.54%)	816 (9.75%)	1,433 (13.78%)	1,453 (13.20%)	18 (9.42%)	4,203 (11.59%)
Sex							
Female	1,038 (55.63%)	2,305 (51.95%)	4,465 (53.37%)	5,729 (55.08%)	6,006 (54.56%)	106 (55.50%)	19,649 (54.17%)
Male	827 (44.32%)	2,124 (47.87%)	3,883 (46.41%)	4,654 (44.74%)	4,977 (45.21%)	85 (44.50%)	16,550 (45.63%)
Unknown	1 (0.05%)	8 (0.18%)	18 (0.22%)	19 (0.18%)	26 (0.24%)	0	72 (0.20%)
Race							

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
White	1,207 (64.68%)	3,033 (68.36%)	5,568 (66.56%)	7,097 (68.23%)	7,158 (65.02%)	98 (51.31%)	24,161 (66.61%)
Black or African American	346 (18.54%)	534 (12.04%)	1,011 (12.08%)	1,275 (12.26%)	1,508 (13.70%)	40 (20.94%)	4,714 (13.00%)
Asian	30 (1.61%)	138 (3.11%)	307 (3.67%)	283 (2.72%)	309 (2.81%)	9 (4.71%)	1,076 (2.97%)
Native Hawaiian or Other Pacific Islander	17 (0.91%)	86 (1.94%)	167 (2.00%)	118 (1.13%)	184 (1.67%)	6 (3.14%)	578 (1.59%)
American Indian or Alaska Native	13 (0.70%)	49 (1.10%)	72 (0.86%)	68 (0.65%)	66 (0.60%)	2 (1.05%)	270 (0.74%)
Other Race	116 (6.22%)	215 (4.85%)	482 (5.76%)	474 (4.56%)	750 (6.81%)	25 (13.09%)	2,062 (5.68%)
Unknown	137 (7.34%)	382 (8.61%)	759 (9.07%)	1,087 (10.45%)	1,034 (9.39%)	11 (5.76%)	3,410 (9.40%)
Ethnicity							
Hispanic or Latino	284 (15.22%)	626 (14.11%)	1,271 (15.19%)	1,333 (12.81%)	1,655 (15.03%)	53 (27.75%)	5,222 (14.40%)
Not Hispanic or Latino	1,440 (77.17%)	3,451 (77.78%)	6,477 (77.42%)	8,273 (79.53%)	8,604 (78.15%)	132 (69.11%)	28,377 (78.24%)
Unknown	142 (7.61%)	360 (8.11%)	618 (7.39%)	796 (7.65%)	750 (6.81%)	6 (3.14%)	2,672 (7.37%)
Comorbidity							
Asthma	223 (11.95%)	560 (12.62%)	1,125 (13.45%)	1,523 (14.64%)	1,779 (16.16%)	24 (12.57%)	5,234 (14.43%)
Chronic Lung Disease	129 (6.91%)	318 (7.17%)	609 (7.28%)	870 (8.36%)	1,072 (9.74%)	14 (7.33%)	3,012 (8.30%)
Chronic Obstructive Pulmonary Disease	297 (15.92%)	749 (16.88%)	1,459 (17.44%)	2,203 (21.18%)	2,311 (20.99%)	25 (13.09%)	7,044 (19.42%)

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends.

Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2020

Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 7,620,591 RSV lab results with known results of which 339,578 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends.

Figure 22: Weekly RSV test positivity rate since October 2020

Figure 23: Weekly RSV test positivity rate by season

Rhinovirus

Our rhinovirus study population consists of 83,551 hospitalizations of 66,998 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	5,789 (100.00%)	8,371 (100.00%)	14,249 (100.00%)	15,785 (100.00%)	20,656 (100.00%)	2,148 (100.00%)	66,998 (100.00%)
Age Group							
< 6 months	302 (5.22%)	599 (7.16%)	788 (5.53%)	747 (4.73%)	820 (3.97%)	64 (2.98%)	3,320 (4.96%)
6 - <12 months	191 (3.30%)	293 (3.50%)	411 (2.88%)	411 (2.60%)	444 (2.15%)	28 (1.30%)	1,778 (2.65%)
1 - <2 years	391 (6.75%)	601 (7.18%)	753 (5.28%)	698 (4.42%)	842 (4.08%)	61 (2.84%)	3,346 (4.99%)
2 - 4 years	375 (6.48%)	875 (10.45%)	1,137 (7.98%)	1,006 (6.37%)	1,141 (5.52%)	104 (4.84%)	4,638 (6.92%)
5 - 17 years	470 (8.12%)	863 (10.31%)	1,325 (9.30%)	1,449 (9.18%)	1,688 (8.17%)	151 (7.03%)	5,946 (8.87%)
18 - 49 years	1,341 (23.16%)	1,392 (16.63%)	2,483 (17.43%)	2,994 (18.97%)	4,025 (19.49%)	427 (19.88%)	12,662 (18.90%)
50 - 64 years	1,019 (17.60%)	1,245 (14.87%)	2,299 (16.13%)	2,503 (15.86%)	3,466 (16.78%)	422 (19.65%)	10,954 (16.35%)
65 - 74 years	779 (13.46%)	1,155 (13.80%)	2,237 (15.70%)	2,510 (15.90%)	3,405 (16.48%)	358 (16.67%)	10,444 (15.59%)
75 - 84 years	583 (10.07%)	845 (10.09%)	1,779 (12.49%)	2,124 (13.46%)	3,042 (14.73%)	361 (16.81%)	8,734 (13.04%)
85+ years	338 (5.84%)	503 (6.01%)	1,037 (7.28%)	1,343 (8.51%)	1,783 (8.63%)	172 (8.01%)	5,176 (7.73%)
Sex							
Female	2,973 (51.36%)	4,119 (49.21%)	7,164 (50.28%)	7,913 (50.13%)	10,297 (49.85%)	1,117 (52.00%)	33,583 (50.13%)
Male	2,804 (48.44%)	4,231 (50.54%)	7,044 (49.44%)	7,835 (49.64%)	10,294 (49.84%)	1,012 (47.11%)	33,220 (49.58%)
Other	0	0	0	0	1 (0.00%)	0	1 (0.00%)
Unknown	12 (0.21%)	21 (0.25%)	41 (0.29%)	37 (0.23%)	64 (0.31%)	19 (0.88%)	194 (0.29%)
Race							
White	3,718 (64.23%)	5,511 (65.83%)	9,120 (64.00%)	9,768 (61.88%)	12,926 (62.58%)	1,333 (62.06%)	42,376 (63.25%)
Black or African American	927 (16.01%)	1,252 (14.96%)	2,178 (15.29%)	2,460 (15.58%)	3,383 (16.38%)	402 (18.72%)	10,602 (15.82%)
Asian	135 (2.33%)	190 (2.27%)	344 (2.41%)	317 (2.01%)	426 (2.06%)	31 (1.44%)	1,443 (2.15%)
Native Hawaiian or Other Pacific Islander	62 (1.07%)	71 (0.85%)	77 (0.54%)	94 (0.60%)	127 (0.61%)	13 (0.61%)	444 (0.66%)
American Indian or Alaska Native	44 (0.76%)	79 (0.94%)	120 (0.84%)	94 (0.60%)	127 (0.61%)	15 (0.70%)	479 (0.71%)
Other Race	377 (6.51%)	583 (6.96%)	1,059 (7.43%)	1,445 (9.15%)	1,805 (8.74%)	166 (7.73%)	5,435 (8.11%)
Unknown	526 (9.09%)	685 (8.18%)	1,351 (9.48%)	1,607 (10.18%)	1,862 (9.01%)	188 (8.75%)	6,219 (9.28%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Ethnicity							
Hispanic or Latino	685 (11.83%)	1,193 (14.25%)	2,224 (15.61%)	2,755 (17.45%)	3,521 (17.05%)	345 (16.06%)	10,723 (16.00%)
Not Hispanic or Latino	4,629 (79.96%)	6,573 (78.52%)	10,969 (76.98%)	11,915 (75.48%)	15,838 (76.68%)	1,701 (79.19%)	51,625 (77.05%)
Unknown	475 (8.21%)	605 (7.23%)	1,056 (7.41%)	1,115 (7.06%)	1,297 (6.28%)	102 (4.75%)	4,650 (6.94%)
Comorbidity							
Asthma	1,142 (19.73%)	1,483 (17.72%)	2,566 (18.01%)	2,918 (18.49%)	3,837 (18.58%)	398 (18.53%)	12,344 (18.42%)
Chronic Lung Disease	635 (10.97%)	750 (8.96%)	1,246 (8.74%)	1,317 (8.34%)	2,017 (9.76%)	198 (9.22%)	6,163 (9.20%)
Chronic Obstructive Pulmonary Disease	1,161 (20.06%)	1,457 (17.41%)	2,571 (18.04%)	2,716 (17.21%)	3,885 (18.81%)	450 (20.95%)	12,240 (18.27%)

Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends.

Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 2,145,040 rhinovirus lab results with known results of which 321,893 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends.

Figure 26: Weekly rhinovirus test positivity rate since October 2020

Figure 27: Weekly rhinovirus test positivity rate by season

Infants and children (age 0-4)

Our infants and children study population consists of 43,433 hospitalizations of 34,820 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	2,962 (100.00%)	6,641 (100.00%)	9,226 (100.00%)	7,682 (100.00%)	7,891 (100.00%)	418 (100.00%)	34,820 (100.00%)
Age Group							
< 6 months	1,062 (35.85%)	2,240 (33.73%)	2,981 (32.31%)	2,458 (32.00%)	2,198 (27.85%)	116 (27.75%)	11,055 (31.75%)
6 - <12 months	436 (14.72%)	1,017 (15.31%)	1,459 (15.81%)	1,331 (17.33%)	1,330 (16.85%)	53 (12.68%)	5,626 (16.16%)
1 - <2 years	738 (24.92%)	1,422 (21.41%)	1,996 (21.63%)	1,746 (22.73%)	1,967 (24.93%)	110 (26.32%)	7,979 (22.91%)
2 - 4 years	726 (24.51%)	1,962 (29.54%)	2,790 (30.24%)	2,147 (27.95%)	2,396 (30.36%)	139 (33.25%)	10,160 (29.18%)
Sex							

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Female	1,293 (43.65%)	2,800 (42.16%)	3,956 (42.88%)	3,324 (43.27%)	3,439 (43.58%)	183 (43.78%)	14,995 (43.06%)
Male	1,669 (56.35%)	3,839 (57.81%)	5,269 (57.11%)	4,355 (56.69%)	4,450 (56.39%)	235 (56.22%)	19,817 (56.91%)
Unknown	0	2 (0.03%)	1 (0.01%)	3 (0.04%)	2 (0.03%)	0	8 (0.02%)
Race							
White	1,575 (53.17%)	3,826 (57.61%)	5,024 (54.45%)	3,942 (51.31%)	4,005 (50.75%)	226 (54.07%)	18,598 (53.41%)
Black or African American	572 (19.31%)	1,028 (15.48%)	1,444 (15.65%)	1,235 (16.08%)	1,295 (16.41%)	80 (19.14%)	5,654 (16.24%)
Asian	97 (3.27%)	289 (4.35%)	483 (5.24%)	327 (4.26%)	299 (3.79%)	8 (1.91%)	1,503 (4.32%)
Native Hawaiian or Other Pacific Islander	84 (2.84%)	191 (2.88%)	243 (2.63%)	233 (3.03%)	254 (3.22%)	11 (2.63%)	1,016 (2.92%)
American Indian or Alaska Native	37 (1.25%)	101 (1.52%)	130 (1.41%)	67 (0.87%)	62 (0.79%)	4 (0.96%)	401 (1.15%)
Other Race	366 (12.36%)	679 (10.22%)	1,067 (11.57%)	1,027 (13.37%)	1,211 (15.35%)	67 (16.03%)	4,417 (12.69%)
Unknown	231 (7.80%)	527 (7.94%)	835 (9.05%)	851 (11.08%)	765 (9.69%)	22 (5.26%)	3,231 (9.28%)
Ethnicity							
Hispanic or Latino	710 (23.97%)	1,551 (23.35%)	2,489 (26.98%)	2,175 (28.31%)	2,378 (30.14%)	126 (30.14%)	9,429 (27.08%)
Not Hispanic or Latino	2,052 (69.28%)	4,633 (69.76%)	6,158 (66.75%)	5,088 (66.23%)	5,039 (63.86%)	276 (66.03%)	23,246 (66.76%)
Unknown	200 (6.75%)	457 (6.88%)	579 (6.28%)	419 (5.45%)	474 (6.01%)	16 (3.83%)	2,145 (6.16%)
Virus							
COVID	499 (16.85%)	1,422 (21.41%)	755 (8.18%)	793 (10.32%)	518 (6.56%)	21 (5.02%)	4,008 (11.51%)
HMPV	22 (0.74%)	493 (7.42%)	786 (8.52%)	450 (5.86%)	511 (6.48%)	7 (1.67%)	2,269 (6.52%)
RSV	880 (29.71%)	1,823 (27.45%)	3,303 (35.80%)	2,540 (33.06%)	2,512 (31.83%)	79 (18.90%)	11,137 (31.98%)
influenza	49 (1.65%)	169 (2.54%)	591 (6.41%)	513 (6.68%)	592 (7.50%)	8 (1.91%)	1,922 (5.52%)
parainfluenza	253 (8.54%)	366 (5.51%)	702 (7.61%)	524 (6.82%)	511 (6.48%)	46 (11.00%)	2,402 (6.90%)
rhinovirus	1,259 (42.51%)	2,368 (35.66%)	3,089 (33.48%)	2,862 (37.26%)	3,247 (41.15%)	257 (61.48%)	13,082 (37.57%)
Comorbidity							
Asthma	224 (7.56%)	417 (6.28%)	623 (6.75%)	610 (7.94%)	734 (9.30%)	29 (6.94%)	2,637 (7.57%)
Chronic Lung Disease	26 (0.88%)	41 (0.62%)	65 (0.70%)	58 (0.76%)	63 (0.80%)	3 (0.72%)	256 (0.74%)
Chronic Obstructive Pulmonary Disease	5 (0.17%)	11 (0.17%)	14 (0.15%)	15 (0.20%)	13 (0.16%)	1 (0.24%)	59 (0.17%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses.

Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five

Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five

Test positivity rate over time

We included 6,784,169 lab results with known results of infants and children under age five. Of those tests, 748,977 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30.

Figure 30: Weekly test positivity rate since October 2020 for infants and children under five

Older adults (age 65 and over)

Our older adults study population consists of 458,665 hospitalizations of 419,052 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	88,813 (100.00%)	101,934 (100.00%)	79,803 (100.00%)	80,180 (100.00%)	66,146 (100.00%)	2,176 (100.00%)	419,052 (100.00%)
Age Group							
65 - 74 years	38,225 (43.04%)	39,893 (39.14%)	26,961 (33.78%)	27,264 (34.00%)	23,381 (35.35%)	802 (36.86%)	156,526 (37.35%)
75 - 84 years	32,279 (36.34%)	38,006 (37.28%)	31,015 (38.86%)	31,603 (39.42%)	26,121 (39.49%)	860 (39.52%)	159,884 (38.15%)
85+ years	18,309 (20.62%)	24,035 (23.58%)	21,827 (27.35%)	21,313 (26.58%)	16,644 (25.16%)	514 (23.62%)	102,642 (24.49%)
Sex							
Female	43,577 (49.07%)	51,180 (50.21%)	42,022 (52.66%)	42,069 (52.47%)	35,492 (53.66%)	1,093 (50.23%)	215,433 (51.41%)
Male	44,879 (50.53%)	50,351 (49.40%)	37,442 (46.92%)	37,777 (47.12%)	30,401 (45.96%)	1,050 (48.25%)	201,900 (48.18%)
Unknown	357 (0.40%)	403 (0.40%)	339 (0.42%)	334 (0.42%)	253 (0.38%)	33 (1.52%)	1,719 (0.41%)
Race							
White	65,545 (73.80%)	77,872 (76.39%)	60,793 (76.18%)	59,448 (74.14%)	49,581 (74.96%)	1,599 (73.48%)	314,838 (75.13%)
Black or African American	9,579 (10.79%)	10,039 (9.85%)	7,284 (9.13%)	8,148 (10.16%)	6,494 (9.82%)	212 (9.74%)	41,756 (9.96%)
Asian	1,285 (1.45%)	1,442 (1.41%)	1,474 (1.85%)	1,739 (2.17%)	1,582 (2.39%)	58 (2.67%)	7,580 (1.81%)
Native Hawaiian or Other Pacific Islander	155 (0.17%)	189 (0.19%)	164 (0.21%)	164 (0.20%)	153 (0.23%)	9 (0.41%)	834 (0.20%)
American Indian or Alaska Native	242 (0.27%)	312 (0.31%)	298 (0.37%)	290 (0.36%)	255 (0.39%)	10 (0.46%)	1,407 (0.34%)
Other Race	2,303 (2.59%)	2,075 (2.04%)	2,020 (2.53%)	2,550 (3.18%)	2,633 (3.98%)	97 (4.46%)	11,678 (2.79%)
Unknown	9,704 (10.93%)	10,005 (9.82%)	7,770 (9.74%)	7,841 (9.78%)	5,448 (8.24%)	191 (8.78%)	40,959 (9.77%)
Ethnicity							
Hispanic or Latino	4,422 (4.98%)	3,859 (3.79%)	3,706 (4.64%)	4,635 (5.78%)	4,611 (6.97%)	171 (7.86%)	21,404 (5.11%)
Not Hispanic or Latino	73,633 (82.91%)	87,887 (86.22%)	68,660 (86.04%)	68,305 (85.19%)	56,931 (86.07%)	1,886 (86.67%)	357,302 (85.26%)
Unknown	10,758 (12.11%)	10,188 (9.99%)	7,437 (9.32%)	7,240 (9.03%)	4,604 (6.96%)	119 (5.47%)	40,346 (9.63%)
Virus							

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
COVID	84,582 (95.24%)	91,794 (90.05%)	54,721 (68.57%)	49,283 (61.47%)	22,732 (34.37%)	942 (43.29%)	304,054 (72.56%)
HMPV	29 (0.03%)	1,212 (1.19%)	2,373 (2.97%)	2,138 (2.67%)	2,933 (4.43%)	30 (1.38%)	8,715 (2.08%)
RSV	510 (0.57%)	1,553 (1.52%)	3,126 (3.92%)	5,184 (6.47%)	5,475 (8.28%)	60 (2.76%)	15,908 (3.80%)
influenza	1,473 (1.66%)	3,883 (3.81%)	12,459 (15.61%)	15,136 (18.88%)	23,916 (36.16%)	139 (6.39%)	57,006 (13.60%)
parainfluenza	519 (0.58%)	989 (0.97%)	2,071 (2.60%)	2,462 (3.07%)	2,860 (4.32%)	114 (5.24%)	9,015 (2.15%)
rhinovirus	1,700 (1.91%)	2,503 (2.46%)	5,053 (6.33%)	5,977 (7.45%)	8,230 (12.44%)	891 (40.95%)	24,354 (5.81%)
Comorbidity							
Asthma	6,984 (7.86%)	9,129 (8.96%)	8,485 (10.63%)	9,149 (11.41%)	8,615 (13.02%)	274 (12.59%)	42,636 (10.17%)
Chronic Lung Disease	6,636 (7.47%)	8,206 (8.05%)	7,348 (9.21%)	7,498 (9.35%)	7,462 (11.28%)	274 (12.59%)	37,424 (8.93%)
Chronic Obstructive Pulmonary Disease	15,895 (17.90%)	22,356 (21.93%)	19,483 (24.41%)	20,567 (25.65%)	18,238 (27.57%)	608 (27.94%)	97,147 (23.18%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in `Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older

Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older

Test positivity rate over time

We included 19,253,128 lab results with known results of adults aged 65 and over. Of those tests, 1,321,578 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33.

Figure 33: Weekly test positivity rate since October 2020 for adults 65 years or older

Discussion and conclusion

In the last week of October 2025, respiratory virus-associated hospitalizations accounted for 1.3% of all hospitalizations, a decrease from 1.8% at the beginning of the month (-31.8%). COVID-associated hospitalizations decreased substantially, from 0.7% to 0.2% of all hospitalizations (-68.2%), and rhinovirus-associated hospitalizations decreased slightly to 0.7% of all hospitalizations. Influenza-, HMPV-, parainfluenza-, and RSV-associated hospitalizations all remained low and stable across the month.

RSV and influenza test positivity increased notably (+165.9% and +85.3%, respectively), while COVID test positivity fell sharply (–51.1%). Parainfluenza test positivity increased slightly (+17.4%), HMPV remained steady and low, and rhinovirus continued to show the highest positivity levels (19.3%). These data suggest that respiratory virus–associated hospitalizations remained low overall; at the end of October rhinovirus

accounted for the largest proportion of virus-associated hospitalizations and had the highest rate of test positivity. At the same time, increases in RSV and influenza test positivity were observed in the overall population, potentially reflecting early signs of seasonal circulation.

In the population aged 0–4 years, respiratory virus–associated hospitalizations remained relatively stable throughout October 2025 and are now at a rate of 2.0% of all hospitalizations in this age group. For the second month in a row, the rate of RSV-associated hospitalizations more than doubled; however the overall rate continues to represent a small proportion of all hospitalizations within this age group (0.7%). COVID-, influenza-, HMPV-, parainfluenza-, and rhinovirus-associated hospitalizations remained relatively stable and low across the month.

In this pediatric population, RSV test positivity more than doubled (+134.6%), and influenza test positivity increased moderately (+65.2%). COVID and HMPV test positivity declined (−56.0% and −55.8%, respectively), while parainfluenza rose slightly (+20.4%). Rhinovirus remained the virus with the highest test positivity rate (46.3%) despite a slight decrease (−8.3%). These data suggest that respiratory virus–associated hospitalizations are at moderate levels among young children, with rhinovirus accounting for the largest proportion in both hospitalizations and test positivity, and the rate of RSV- and influenza-associated hospitalizations more than doubled, suggesting rising circulation among young children.

Among adults aged 65 years and older, respiratory virus–associated hospitalizations accounted for 1.2% of all hospitalizations in the last week of October 2025, a decrease from 2.1% at the beginning of the month (-41.5%). Rhinovirus-associated hospitalizations were stable and accounted for 0.6% of all hospitalizations in this age group, while COVID-associated hospitalizations represented 0.4% and declined steadily across the month. RSV-, HMPV-, influenza-, and parainfluenza-associated hospitalizations remained low and stable throughout the month.

COVID test positivity declined substantially (−56.2%), while RSV and influenza test positivity increased (+259.0% and +53.7%, respectively). HMPV and parainfluenza remained relatively stable across the month, and rhinovirus continued to have the highest positivity rate (8.1%) with a slight decline (−11.2%). These data indicate that respiratory virus–associated hospitalizations remained low among older adults, with RSV and influenza showing early signs of increased positivity across the month.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed November 10, 2025. These are raw counts and post-stratification methods

have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., … Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., … Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518. https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy